Amylyx Pharmaceuticals, Inc. Stock News

The final trades of the day with the Fast Money traders.

Amylyx Pharmaceuticals, Inc. (AMLX) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to loss of $0.93 per share a y

With multiple blockbuster drugs going off patent this decade, pharma companies are expected to ratchet up their M&A activities. These three companies sport high-value assets that could attract suitors

Amylyx (AMLX) progresses with the phase II study of pipeline candidate AMX0035 for the treatment of Wolfram syndrome as it doses the first patient.

Generally speaking, biotech stocks to buy offer investors an excellent opportunity for significant upside success. According to Grand View Research, the global market size for the industry reached $1.

Amylyx Pharmaceuticals scored a major regulatory approval with its amyotrophic lateral sclerosis (ALS) drug last year. The drug's sales far surpassed expectations in its first quarter on the market in

Amylyx's new ALS treatment crushed Wall Street's fourth-quarter expectations, pushing AMLX stock above its 50-day line Tuesday. The post Amylyx, A Top 5% Biotech Stock, Just Scored A Huge Win In ALS T

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee -

David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 20

AMLX got relyvrio approved through an interesting set of events. There are questions surrounding high price, low benefit, trial design, and so on.

Historic 2022 inflation lifted energy and value stocks while sinking growth plays. The post 100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make Miracles appeared first on Investor's

Amylyx Pharmaceuticals, Inc. received a surprise approval for Relyvrio in ALS. The approval is great for the once-small company.

The IPO market has been slow this year as investors' risk appetite for new issues hit a record low.

The neuroscience renaissance is here. Biotech stocks are soaring this year on expectations for new treatments in brain-health disorders.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee